Cancer Res Treat.  2015 Oct;47(4):844-852. 10.4143/crt.2014.124.

Expression of PEG10 Is Associated with Poor Survival and Tumor Recurrence in Hepatocellular Carcinoma

• Bang H
• Ha SY
• Hwang SH
• Park CK

• KMID: 2403404
• DOI: http://doi.org/10.4143/crt.2014.124

Abstract

PURPOSE
Paternally expressed gene 10 (PEG10), first identified as an imprinted gene, is paternally expressed and maternally silenced. In hepatocellular carcinoma (HCC), PEG10 has been identified as a potential target gene located within the amplified 7q21 locus. The purpose of this study was to investigate the expression of PEG10 protein in HCC and evaluate its prognostic significance.
MATERIALS AND METHODS
PEG10 protein expression was examined by immunohistochemistry in tumor tissues from 218 HCC patients undergoing curative resection. Furthermore, the relationships between PEG10 expression and clinicopathologic features or postoperative survival of HCC patients were evaluated. The median follow-up period was 119.8 months for survivors.
RESULTS
PEG10 expression was observed in 148 of the 218 HCCs (67.9%) and was significantly correlated with younger age, female, higher Edmondson grade, microvascular invasion, intrahepatic metastasis, higher American Joint Committee on Cancer T-stage, and higher alpha-fetoprotein level. PEG10 expression was an independent predictor of early recurrence (p=0.013), and it showed an unfavorable influence on recurrence-free survival (p < 0.001). A subgroup analysis showed that among patients with alpha-fetoprotein < or = 20 ng/mL (80 patients), the PEG10-positive group also showed an unfavorable influence on recurrence-free survival (p=0.002). Moreover, a multivariate survival analysis identified PEG10 as an independent predictor of shorter recurrence-free survival (p=0.005). PEG10 expression showed an unfavorable influence on overall survival (p=0.007) but was not an independent predictor of shorter overall survival (p=0.128).
CONCLUSION
PEG10 protein could be a potential biomarker predicting early recurrence and recurrence-free survival in HCC patients after curative resection, even in those with normal serum alpha-fetoprotein levels.

Keyword

PEG10; Hepatocellular carcinoma; Recurrence

MeSH Terms

alpha-Fetoproteins
Carcinoma, Hepatocellular*
Female
Follow-Up Studies
Humans
Immunohistochemistry
Joints
Neoplasm Metastasis
Recurrence*
Survivors
alpha-Fetoproteins

Figure

• 

  Fig. 1. Immunostaining of paternally expressed gene 10 in normal liver shows no immunoreactivity in normal hepatocytes (horseradish peroxidase staining, ×200).

• 

  Fig. 2. Immunostaining of paternally expressed gene 10 in hepatocellular carcinomas showing positive cytoplasmic expression (A) or negative expression (B) (horseradish peroxidase staining, ×200).

• 

  Fig. 3. Kaplan-Meier survival curves showing recurrence-free survival among all patients (A), patients with α-fetoprotein (AFP) ≤ 20 ng/mL (B), patients with tumor size ≤ 5.0 cm (C), and patients at American Joint Committee on Cancer (AJCC) T-stage 1 (D) according to the paternally expressed gene 10 (PEG10) expression.

• 

  Fig. 4. Kaplan-Meier survival curves showing overall survival for paternally expressed gene 10 (PEG10) expression in 218 hepatocellular carcinomas.

Reference

References

1. Regimbeau JM, Abdalla EK, Vauthey JN, Lauwers GY, Durand F, Nagorney DM, et al. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol. 2004; 85:36–41.

2. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol. 1997; 8:117–36.

3. Dobashi Y, Goto A, Endo T, Ooi A. Genetic aberrations as the targets of oncology research: involvement of paraffin-embedded tissues. Histol Histopathol. 2014; 29:191–205.

4. Ono R, Kobayashi S, Wagatsuma H, Aisaka K, Kohda T, Kaneko-Ishino T, et al. A retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. Genomics. 2001; 73:232–7.

5. Li CM, Margolin AA, Salas M, Memeo L, Mansukhani M, Hibshoosh H, et al. PEG10 is a c-MYC target gene in cancer cells. Cancer Res. 2006; 66:665–72.

6. Liu DC, Yang ZL, Jiang S. Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Pathol Oncol Res. 2011; 17:859–66.

7. Tsou AP, Chuang YC, Su JY, Yang CW, Liao YL, Liu WK, et al. Overexpression of a novel imprinted gene, PEG10, in human hepatocellular carcinoma and in regenerating mouse livers. J Biomed Sci. 2003; 10:625–35.

8. Ip WK, Lai PB, Wong NL, Sy SM, Beheshti B, Squire JA, et al. Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma. Cancer Lett. 2007; 250:284–91.

9. Tsuji K, Yasui K, Gen Y, Endo M, Dohi O, Zen K, et al. PEG10 is a probable target for the amplification at 7q21 detected in hepatocellular carcinoma. Cancer Genet Cytogenet. 2010; 198:118–25.

10. Dong H, Zhang H, Liang J, Yan H, Chen Y, Shen Y, et al. Digital karyotyping reveals probable target genes at 7q21.3 locus in hepatocellular carcinoma. BMC Med Genomics. 2011; 4:60.

11. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954; 7:468–503.

12. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 1997; 25:87–92.

13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer;2010. p. 191–5.

14. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19:329–38.

15. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003; 38:200–7.

16. Ahn S, Hyeon J, Park CK. Metadherin is a prognostic predictor of hepatocellular carcinoma after curative hepatectomy. Gut Liver. 2013; 7:206–12.

17. Okabe H, Satoh S, Furukawa Y, Kato T, Hasegawa S, Nakajima Y, et al. Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res. 2003; 63:3043–8.

18. Ono R, Nakamura K, Inoue K, Naruse M, Usami T, Wakisaka-Saito N, et al. Deletion of Peg10, an imprinted gene acquired from a retrotransposon, causes early embryonic lethality. Nat Genet. 2006; 38:101–6.

19. Wang C, Xiao Y, Hu Z, Chen Y, Liu N, Hu G. PEG10 directly regulated by E2Fs might have a role in the development of hepatocellular carcinoma. FEBS Lett. 2008; 582:2793–8.

20. Jie X, Lang C, Jian Q, Chaoqun L, Dehua Y, Yi S, et al. Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells. Oncogene. 2007; 26:5741–51.

21. Lux A, Beil C, Majety M, Barron S, Gallione CJ, Kuhn HM, et al. Human retroviral gag- and gag-pol-like proteins interact with the transforming growth factor-beta receptor activin receptor-like kinase 1. J Biol Chem. 2005; 280:8482–93.

22. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001; 5:145–59.

23. Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology. 1990; 12:1420–32.

24. Cucchetti A, Piscaglia F, Caturelli E, Benvegnu L, Vivarelli M, Ercolani G, et al. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol. 2009; 16:413–22.

25. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000; 89:500–7.